G. Ghassabeh

发表

Single-domain antibodies as building blocks for novel therapeutics.

S. Muyldermans, D. Saerens, G. Ghassabeh, 2008, Current opinion in pharmacology.

A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation

S. Muyldermans, M. Behdani, D. Shahbazzadeh, 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Isolation of Antigen-Specific Nanobodies

S. Muyldermans, D. Saerens, G. Ghassabeh, 2010 .

Antibody technology in proteomics.

S. Muyldermans, D. Saerens, G. Ghassabeh, 2008, Briefings in functional genomics & proteomics.

Antibody technology in proteomics 277

S. Muyldermans, D. Saerens, G. Ghassabeh, 2008 .

The metastatic T‐cell hybridoma antigen/P‐selectin glycoprotein ligand 1 is required for hematogenous metastasis of lymphomas

H. Verschueren, P. De Baetselier, D. Vanhecke, 2007, International journal of cancer.

Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo during different pathologies

F. Brombacher, L. Brys, A. Beschin, 2006 .

Peroxisome proliferator-activated receptor γ (PPARγ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer

L. Brys, G. Raes, P. Baetselier, 2006 .

Alternatively Activated Myeloid Cells Limit Pathogenicity Associated with African Trypanosomiasis through the IL-10 Inducible Gene Selenoprotein P1

P. De Baetselier, M. Guilliams, L. Brys, 2008, The Journal of Immunology.

Arginase-1 and Ym1 Are Markers for Murine, but Not Human, Alternatively Activated Myeloid Cells

P. De Baetselier, R. Van den Bergh, G. Raes, 2005, The Journal of Immunology.

Macrophage galactose‐type C‐type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation

B. Dahal, P. De Baetselier, G. Vanham, 2005, Journal of leukocyte biology.

Gene Selenoprotein P Trypanosomiasis through the IL-10 Inducible Pathogenicity Associated with African Alternatively Activated Myeloid Cells Limit

Geert, M. Guilliams, L. Brys, 2008 .

conditions associated myeloid cells elicited in vivo in different pathologic - Identification of a common gene signature for type II cytokine

F. Brombacher, L. Brys, A. Beschin, 2013 .

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ (PPARγ) LIGANDS REVERSE CTL SUPPRESSION BY ALTERNATIVELY ACTIVATED (M2) MACROPHAGES IN CANCER Running title: Modulating M2-mediated suppression in cancer

L. Brys, G. Raes, P. Baetselier, 2006 .

Peroxisome proliferator-activated receptor (cid:1) (PPAR (cid:1) ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer

L. Brys, G. Raes, J. A. Ginderachter, 2006 .

Reactive Oxygen Species and 12/15-Lipoxygenase Contribute to the Antiproliferative Capacity of Alternatively Activated Myeloid Cells Elicited during Helminth Infection

F. Brombacher, L. Brys, A. Beschin, 2005 .

Reactive Oxygen Species and 12/15-Lipoxygenase Contribute to the Antiproliferative Capacity of Alternatively Activated Myeloid Cells Elicited during Helminth Infection 1

F. Brombacher, L. Brys, A. Beschin, 2005, The Journal of Immunology.

Helminth Infection Activated Myeloid Cells Elicited during Antiproliferative Capacity of Alternatively 12 / 15-Lipoxygenase Contribute to the Reactive Oxygen Species and Brombacher and

F. Brombacher, L. Brys, A. Beschin, 2005 .

Alternatively activated macrophages in protozoan infections.

P. De Baetselier, A. Beschin, G. Raes, 2007, Current opinion in immunology.

Activated Myeloid Cells Murine, but Not Human, Alternatively Arginase-1 and Ym1 Are Markers for

G. Raes, P. Baetselier, G. Ghassabeh, 2005 .

Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions.

P. De Baetselier, F. Brombacher, J. V. Van Ginderachter, 2006, Blood.

Using microdialysis to analyse the passage of monovalent nanobodies through the blood–brain barrier

Y. Michotte, S. Muyldermans, P. De Baetselier, 2012, British journal of pharmacology.

TRIM28 and β-Actin Identified via Nanobody-Based Reverse Proteomics Approach as Possible Human Glioblastoma Biomarkers

M. E. Ruaro, S. Muyldermans, H. Motaln, 2014, PloS one.

Secretory Leukocyte Protease Inhibitor in Cancer Development

N. Devoogdt, H. Revets, P. Baetselier, 2004, Annals of the New York Academy of Sciences.

The Tumor-Promoting Effect of TNF-α Involves the Induction of Secretory Leukocyte Protease Inhibitor1

P. De Baetselier, N. Devoogdt, H. Revets, 2006, The Journal of Immunology.

A Novel Soluble Immune-Type Receptor (SITR) in Teleost Fish: Carp SITR Is Involved in the Nitric Oxide-Mediated Response to a Protozoan Parasite

V. Schijns, H. Savelkoul, G. Wiegertjes, 2011, PloS one.

A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior*

S. Muyldermans, Mingdong Huang, P. Declerck, 2016, The Journal of Biological Chemistry.

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

B. Lambrecht, S. Marqusee, N. Callewaert, 2023, bioRxiv.

Generation and characterization of non-competitive furin-inhibiting nanobodies.

S. Muyldermans, I. Lindberg, W. V. D. Van de Ven, 2012, The Biochemical journal.

Nanobodies, Single-Domain Antigen-Binding Fragments of Camelid Heavy-Chain Antibodies

S. Muyldermans, D. Saerens, G. Ghassabeh, 2010 .

Generation and characterization of non-competitive furin-inhibiting nanobodies.

S. Muyldermans, I. Lindberg, W. V. D. Van de Ven, 2012, The Biochemical journal.